XML 51 R36.htm IDEA: XBRL DOCUMENT v3.25.1
REVENUES - Summary of Total Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Total revenues $ 6,667 $ 6,686
U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,668 4,633
Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,084 1,159
Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 915 894
Total product sales    
Disaggregation of Revenue [Line Items]    
Total revenues 6,613 6,647
Total product sales | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 4,631 4,609
Total product sales | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 1,073 1,144
Total product sales | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 909 894
Total HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 4,587 4,342
Total HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 3,664 3,405
Total HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 553 596
Total HIV | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 370 342
Biktarvy    
Disaggregation of Revenue [Line Items]    
Total revenues 3,150 2,946
Biktarvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 2,474 2,315
Biktarvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 375 365
Biktarvy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 301 265
Descovy    
Disaggregation of Revenue [Line Items]    
Total revenues 586 426
Descovy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 538 371
Descovy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 21 26
Descovy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 27 29
Genvoya    
Disaggregation of Revenue [Line Items]    
Total revenues 364 403
Genvoya | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 305 332
Genvoya | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 40 49
Genvoya | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 19 21
Odefsey    
Disaggregation of Revenue [Line Items]    
Total revenues 281 310
Odefsey | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 215 223
Odefsey | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 57 76
Odefsey | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 10 11
Symtuza - Revenue share    
Disaggregation of Revenue [Line Items]    
Total revenues 114 141
Symtuza - Revenue share | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 82 104
Symtuza - Revenue share | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 29 33
Symtuza - Revenue share | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 3 3
Other HIV    
Disaggregation of Revenue [Line Items]    
Total revenues 91 117
Other HIV | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 50 60
Other HIV | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 31 45
Other HIV | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 10 12
Total Liver Disease    
Disaggregation of Revenue [Line Items]    
Total revenues 758 737
Total Liver Disease | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 335 385
Total Liver Disease | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 168 137
Total Liver Disease | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 256 215
Sofosbuvir/Velpatasvir    
Disaggregation of Revenue [Line Items]    
Total revenues 346 405
Sofosbuvir/Velpatasvir | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 166 248
Sofosbuvir/Velpatasvir | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 80 79
Sofosbuvir/Velpatasvir | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 99 78
Vemlidy    
Disaggregation of Revenue [Line Items]    
Total revenues 252 225
Vemlidy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 100 95
Vemlidy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 12 11
Vemlidy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 140 119
Other Liver Disease    
Disaggregation of Revenue [Line Items]    
Total revenues 161 107
Other Liver Disease | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 68 42
Other Liver Disease | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 76 47
Other Liver Disease | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 17 19
Veklury    
Disaggregation of Revenue [Line Items]    
Total revenues 302 555
Veklury | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 199 315
Veklury | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 22 70
Veklury | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 82 169
Total Oncology    
Disaggregation of Revenue [Line Items]    
Total revenues 757 789
Total Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 381 431
Total Oncology | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 255 262
Total Oncology | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 121 96
Total Cell Therapy    
Disaggregation of Revenue [Line Items]    
Total revenues 464 480
Total Cell Therapy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 200 225
Total Cell Therapy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 180 195
Total Cell Therapy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 84 60
Tecartus    
Disaggregation of Revenue [Line Items]    
Total revenues 78 100
Tecartus | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 40 55
Tecartus | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 31 36
Tecartus | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 8 8
Yescarta    
Disaggregation of Revenue [Line Items]    
Total revenues 386 380
Yescarta | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 160 170
Yescarta | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 149 158
Yescarta | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 77 52
Trodelvy    
Disaggregation of Revenue [Line Items]    
Total revenues 293 309
Trodelvy | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 181 206
Trodelvy | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 75 68
Trodelvy | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 37 36
Total Other    
Disaggregation of Revenue [Line Items]    
Total revenues 209 224
Total Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 52 73
Total Other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 76 79
Total Other | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 81 71
AmBisome    
Disaggregation of Revenue [Line Items]    
Total revenues 139 144
AmBisome | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 5 14
AmBisome | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 67 70
AmBisome | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 66 60
Other    
Disaggregation of Revenue [Line Items]    
Total revenues 70 80
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 47 59
Other | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 9 9
Other | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues 14 12
Royalty, contract and other revenues    
Disaggregation of Revenue [Line Items]    
Total revenues 54 39
Royalty, contract and other revenues | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenues 37 23
Royalty, contract and other revenues | Europe    
Disaggregation of Revenue [Line Items]    
Total revenues 11 15
Royalty, contract and other revenues | Rest of World    
Disaggregation of Revenue [Line Items]    
Total revenues $ 6 $ 1